UNLABELLED: Self-administered questionnaires were completed by patients undergoing chemotherapy for stage III colon cancer (n=1095) and metastatic colorectal cancer (n=875). We describe the prevalence of a wide-range of health-related dietary patterns and lifestyle behaviors among colorectal cancer patients with stage III and metastatic disease and report notable similarities in these 2 cohorts. BACKGROUND: Cancer patients often pursue lifestyle and dietary changes with the aim to improve outcomes. Using data from 2 large National Cancer Institute-sponsored clinical trials, we report on the dietary and lifestyle practices of patients receiving therapy for stage III colon or metastatic colorectal cancer. PATIENTS AND METHODS: Self-administered questionnaires were completed by patients undergoing chemotherapy for stage III colon cancer (n=1095) and metastatic colorectal cancer (n=875). Descriptive statistical analyses were performed to evaluate anthropometrics, diet, and lifestyle in each cohort. RESULTS: Median body mass index was comparable for stage III and metastatic patients (27.3 vs. 26.5 kg/m2). Stage III patients reported a modestly higher median level of physical activity than metastatic patients (4.6 vs. 3.4 metabolic equivalent task-hours per week). Ten percent of stage III and 9% of metastatic patients reported ongoing cigarette use. Avoidance of alcohol was reported by 47% of stage III and 43% of metastatic patients. Dietary patterns for both groups were comparable with more than 80% of stage III and metastatic patients failing to meet the recommended daily intake of vegetables, fruits, and milk products. Usage of at least 2 multivitamins per week was reported by 49% of stage III and 40% of metastatic patients. Two percent of stage III and 5% of metastatic patients reported vitamin D supplement use. CONCLUSIONS: We observed notable similarities in dietary and lifestyle behaviors between stage III colon and metastatic colorectal cancer patients actively receiving chemotherapy. Future research should aim to elucidate the effect of these behaviors on patient outcomes.
UNLABELLED: Self-administered questionnaires were completed by patients undergoing chemotherapy for stage III colon cancer (n=1095) and metastatic colorectal cancer (n=875). We describe the prevalence of a wide-range of health-related dietary patterns and lifestyle behaviors among colorectal cancerpatients with stage III and metastatic disease and report notable similarities in these 2 cohorts. BACKGROUND:Cancerpatients often pursue lifestyle and dietary changes with the aim to improve outcomes. Using data from 2 large National Cancer Institute-sponsored clinical trials, we report on the dietary and lifestyle practices of patients receiving therapy for stage III colon or metastatic colorectal cancer. PATIENTS AND METHODS: Self-administered questionnaires were completed by patients undergoing chemotherapy for stage III colon cancer (n=1095) and metastatic colorectal cancer (n=875). Descriptive statistical analyses were performed to evaluate anthropometrics, diet, and lifestyle in each cohort. RESULTS: Median body mass index was comparable for stage III and metastatic patients (27.3 vs. 26.5 kg/m2). Stage III patients reported a modestly higher median level of physical activity than metastatic patients (4.6 vs. 3.4 metabolic equivalent task-hours per week). Ten percent of stage III and 9% of metastatic patients reported ongoing cigarette use. Avoidance of alcohol was reported by 47% of stage III and 43% of metastatic patients. Dietary patterns for both groups were comparable with more than 80% of stage III and metastatic patients failing to meet the recommended daily intake of vegetables, fruits, and milk products. Usage of at least 2 multivitamins per week was reported by 49% of stage III and 40% of metastatic patients. Two percent of stage III and 5% of metastatic patients reported vitamin D supplement use. CONCLUSIONS: We observed notable similarities in dietary and lifestyle behaviors between stage III colon and metastatic colorectal cancerpatients actively receiving chemotherapy. Future research should aim to elucidate the effect of these behaviors on patient outcomes.
Authors: Chris M Blanchard; Maxine M Denniston; Frank Baker; Stuart R Ainsworth; Kerry S Courneya; Danette M Hann; Dean H Gesme; Douglas Reding; Thomas Flynn; John S Kennedy Journal: Am J Health Behav Date: 2003 May-Jun
Authors: Ruth E Patterson; Marian L Neuhouser; Monique M Hedderson; Stephen M Schwartz; Leanna J Standish; Deborah J Bowen Journal: J Am Diet Assoc Date: 2003-03
Authors: Ruth E Patterson; Marian L Neuhouser; Monique M Hedderson; Stephen M Schwartz; Leanna J Standish; Deborah J Bowen; Lynn M Marshall Journal: J Altern Complement Med Date: 2002-08 Impact factor: 2.579
Authors: Jeffrey A Meyerhardt; Paul J Catalano; Daniel G Haller; Robert J Mayer; Al B Benson; John S Macdonald; Charles S Fuchs Journal: Cancer Date: 2003-08-01 Impact factor: 6.860
Authors: Jessie A Satia; Marci K Campbell; Joseph A Galanko; Aimee James; Carol Carr; Robert S Sandler Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-06 Impact factor: 4.254
Authors: Stephen L Chan; Anthony W H Chan; Frankie Mo; Brigette B Y Ma; Kenneth C W Wong; Daisy Lam; Florence S T Mok; Anthony T C Chan; Tony Mok; K C Allen Chan Journal: Oncologist Date: 2018-05-25
Authors: Marcin Mardas; Małgorzata Jamka; Radosław Mądry; Jarosław Walkowiak; Marietta Krótkopad; Marta Stelmach-Mardas Journal: Support Care Cancer Date: 2014-10-02 Impact factor: 3.603
Authors: Virginia Sun; Tracy E Crane; Samantha D Slack; Angela Yung; Sarah Wright; Stephen Sentovich; Kurt Melstrom; Marwan Fakih; Robert S Krouse; Cynthia A Thomson Journal: Contemp Clin Trials Date: 2018-03-19 Impact factor: 2.226
Authors: Britni R Belcher; Dong-Woo Kang; Alexandra G Yunker; Christina M Dieli-Conwright Journal: Curr Oncol Rep Date: 2022-07-13 Impact factor: 5.945
Authors: Brendan J Guercio; Sui Zhang; Donna Niedzwiecki; Yanping Li; Ana Babic; Vicente Morales-Oyarvide; Leonard B Saltz; Robert J Mayer; Rex B Mowat; Renaud Whittom; Alexander Hantel; Al Benson; Daniel Atienza; Michael Messino; Hedy Kindler; Alan Venook; Shuji Ogino; Emilie S Zoltick; Meir Stampfer; Kimmie Ng; Kana Wu; Walter C Willett; Edward L Giovannucci; Jeffrey A Meyerhardt; Charles S Fuchs Journal: PLoS One Date: 2018-07-19 Impact factor: 3.240
Authors: Moniek van Zutphen; Hendriek C Boshuizen; Dieuwertje E Kok; Harm van Baar; Anne J M R Geijsen; Evertine Wesselink; Renate M Winkels; Henk K van Halteren; Johannes H W de Wilt; Ellen Kampman; Fränzel J B van Duijnhoven Journal: J Cancer Surviv Date: 2019-10-23 Impact factor: 4.442
Authors: Brendan J Guercio; Sui Zhang; Alan P Venook; Fang-Shu Ou; Donna Niedzwiecki; Heinz-Josef Lenz; Federico Innocenti; Brian C Mullen; Bert H O'Neil; James E Shaw; Blase N Polite; Howard S Hochster; James N Atkins; Richard M Goldberg; Justin C Brown; Eileen M O'Reilly; Robert J Mayer; Charles D Blanke; Charles S Fuchs; Jeffrey A Meyerhardt Journal: JNCI Cancer Spectr Date: 2020-03-31